CACI · CACI INTERNATIONAL CLA

The thesis

CACI International's raised fiscal 2027 guidance and growing funded backlog still support the case after the shares fell to $604.51 on 5 November 2026. The next report (~27 January 2027, est.) settles it: organic growth has to rise above the first quarter's 2.1%, and total backlog has to grow.

The fall is the main change since the 28 October 2026 note. The shares went from a $680.10 close on 3 November 2026, per Morningstar, back to about the $604.01 close of 14 October 2026. Company news over those days showed contract awards, and no outlet reviewed named a company-specific cause. The view here is that this is selling after a fast rise more than damage to the business. A guidance cut or a negative company disclosure would show that view is wrong.

The narrative is maturing: analyst target raises clustered between 21 October 2026 and 27 October 2026, and the shares have since given back those gains despite two further contract announcements.

Bullish and bearish views on CACI INTERNATIONAL CLA

The bull case on CACI INTERNATIONAL CLA (CACI), in brief: Guidance went up. The bear case: Organic growth was 2.1%, compared with 7.2% for fiscal 2026.

Bull case

• Guidance went up. CACI's 21 October 2026 release lifted fiscal 2027 revenue guidance to $10.70–$10.90 billion from $10.65–$10.85 billion. Adjusted earnings per share (EPS) guidance rose to $33.18–$34.08 from $32.96–$33.86, and free cash flow guidance stayed at least $900 million.
• About 61% of awards were new business.
• Funded demand keeps growing. Funded backlog was $6.2 billion at 30 September 2026, up 14.8% year over year, per the same release.
• Contract wins continued after the report. CACI announced a five-year, $185 million Army task order for expeditionary energy and sustainment systems on 29 October 2026. A five-year, $108 million Air Force contract to modernize the DEAMS financial system followed on 3 November 2026.
• Revenue is shifting toward defense. The Form 10-Q for the quarter ended 30 September 2026 shows Department of War revenue of $1,354.3 million, up 14.8%, and federal civilian revenue of $396.4 million, down 3.7%. CACI bought space-technology company ARKA Group on 9 March 2026 for $2,637.7 million, net of cash acquired.
• Analyst targets sit above the shares. MarketBeat's consensus target was $727.70 on 4 November 2026, on nine buy, one hold and one sell ratings. Stifel's target is $925 (23 October 2026) and Cantor Fitzgerald's is $785 (21 October 2026).

Bear case

• Organic growth was 2.1%, compared with 7.2% for fiscal 2026.
• Total backlog is flat. The 10-Q shows total backlog of $34.0 billion at 30 September 2026, up 0.3% from $33.9 billion a year earlier. A PRNewswire commentary on 4 November 2026 said peers from Booz Allen to BigBear.ai reported larger backlogs.
• Free cash flow fell. First-quarter free cash flow was $133.5 million, down 6.6% year over year, per the 21 October 2026 release. Operating cash flow was $161.3 million against $171.1 million, which the 10-Q attributes mainly to working capital timing.
• Federal funding is short-dated. The 10-Q says a continuing resolution signed on 2 September 2026 funds the government only through 11 December 2026. The filing warns that such resolutions can delay new programs and contract awards.
• The fiscal year is changing. The 10-Q says the board approved moving the fiscal year end to 31 December on 20 October 2026, with a transition report for the six months ending 31 December 2026. The 21 October 2026 release frames guidance on fiscal 2027 only, so comparisons will be harder to read until CACI gives an outlook on the new calendar.
• Debt is meaningful and one target is well below the shares. Debt principal was $4,864.4 million against $279.4 million of cash at 30 September 2026, per the 10-Q, and CACI put pro-forma net leverage at 3.7 times at fiscal 2026 year-end. BNP Paribas downgraded the shares to underperform with a $540 target on 6 October 2026.

Price setup

The adjusted close was $604.51 on 5 November 2026, 11.2% below the 52-week high of $680.50 in adjusted daily closes. MarketBeat's one-year range runs from $434.70 to $694.01.

The shares are down 6.7% over three months. The last close sits under the 50-day moving average of $626.36 and above the 200-day moving average of $570.39, both per MarketBeat on 4 November 2026. The $600 invalidation level from the previous note sits just under the last close, so a small further decline would reach it.

The heavy crowding described in the previous note has eased. The 14-day relative strength index (RSI) is 47.1, down from 82.2 on 27 October 2026. The next scheduled test is about three months away, so no earnings date is crowding the shares now.

Catalysts, next 30 days

No company report or dated regulatory decision was found for the 30 days to 6 December 2026. Two later events decide the case.

• 11 December 2026: continuing resolution expires. An extension or full-year funding would ease the award-timing risk the 10-Q describes. A lapse would raise it.
• ~27 January 2027, est.: next results. The date is unconfirmed, and the fiscal-year change could move it. The report shows whether organic growth rises above 2.1%, whether total backlog grows year over year, and how guidance carries over to the new calendar.

What would change the view

The case breaks if CACI cuts the $10.70–$10.90 billion revenue guide or withdraws the at-least-$900 million free-cash-flow outlook. Any outlook restated for the new fiscal calendar would need to carry the same annual pace. A book-to-bill below 1.0 times or organic growth staying near 2.1% in the next report would also weaken it.

On price, a daily close below $600 would end the case as framed here. That close would put the shares under the $604.01 close of 14 October 2026. The case would strengthen with organic growth well above 2.1% and year-over-year total backlog growth in the next report.

What it trades with

CACI trades with US government technology contractors on federal budget news, which makes the 11 December 2026 funding date a shared event for the group. It did not move with all of them on 4 November 2026: the PRNewswire commentary listed CACI down 7.16% and Booz Allen up 2.61%. MarketBeat showed a beta of 0.55 on 4 November 2026, a low reading against the wider market. Its space and counter-drone work adds exposure to programs such as the Space Force's $981 million NITE-STAR contract, a ceiling shared with Rocket Lab, Boeing, Lockheed Martin and Northrop Grumman (17 August 2026).